Renoprotective Effects of Small Interfering RNA Targeting Liver Angiotensinogen in Experimental Chronic Kidney Disease

Hypertension. 2021 May 5;77(5):1600-1612. doi: 10.1161/HYPERTENSIONAHA.120.16876. Epub 2021 Mar 15.

¹ Division of Vascular Medicine and Pharmacology (D.M.B., L.R., E.U., R.v.V., I.M.G., A.H.J.D.), Erasmus MC, University Medical Center Rotterdam, the Netherlands.
² Division of Nephrology and Transplantation, Department of Internal Medicine (D.M.B., E.U., E.J.H.), Erasmus MC, University Medical Center Rotterdam, the Netherlands.
³ Translational Medicine Collaborative Innovation Center, The Second Clinical Medical College (Shenzhen People's Hospital) of Jinan University, China (L.R.).
⁴ Department of Pathology (M.C.C.-v.G.), Erasmus MC, University Medical Center Rotterdam, the Netherlands.
⁵ Attoquant Diagnostics, Vienna, Austria (O.D., M.P.).
⁶ Alnylam Pharmaceuticals, Cambridge, MA (I.Z., J.B.K., S.H., L.M., D.F.).
⁷ Department of Physiology, AstraZeneca-Shenzhen University Joint Institute of Nephrology, Shenzhen University Health Science Center, Shenzhen University, China (X.L.).

^# Contributed equally.

Abstract

[Figure: see text].

Keywords: RNA, small interfering; cardiac hypertrophy; hypertension; renal insufficiency, chronic; renin-angiotensin system.